Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.
Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Jazz Pharmaceuticals plc ( JAZZ ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Director Samantha Pearce - Executive VP & Chief Commercial Officer Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development Philip Johnson - Executive VP & CFO Conference Call Participants Marc Goodman - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Jason Gerberry - BofA Securities, Research Division Ami Fadia - Needham & Company, LLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division David Hoang - Deutsche Bank AG, Research Division Ashwani Verma - UBS Investment Bank, Research Division Joseph Thome - TD Cowen, Research Division Asim Rana - Truist Securities, Inc., Research Division Michael Riad - Morgan Stanley, Research Division Denis Reznik - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $8.13 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $6.61 per share a year ago.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit Bansal.
